Contents

	Page
Chapter 1. Introduction and Background	1
WHAT IS CYSTIC FIBROSIS?	. 2
THE CYSTIC FIBROSIS GENE	. 2
CYSTIC FIBROSIS MUTATION ANALYSIS	
CONTROVERSY ABOUT CYSTIC FIBROSIS CARRIER SCREENING	. 3
SCOPE AND ORGANIZATION OF THIS BACKGROUND PAPER	
CHAPTER 1 REFERENCES	
Chapter 2. Providers, Clientele, and Genetic Services *0	5
THE SURVEY POPULATION	
Genetic Counselors	
Nurses in Genetics	
Demographic Profile of Survey Respondents	
WORK ENVIRONMENTS	
GENETICS CLIENTELE	
FEES AND THIRD-PARTY COVERAGE	
Fees for Genetic Services	
Third-Party Coverage	12
SUMMARY	
CHAPTER 2 REFERENCES	15
Charter 2 Court Film of Court Court Delicity and Deciden	17
Chapter 3. Cystic Fibrosis Carrier Screening: Policies and Practices	. I7
POLICIES AND PRACTICES, SUMMER 1991	
Policies on Cystic Fibrosis Carrier Screening	
Criteria for Cystic Fibrosis Carrier Screening	
Practices Regarding DNA-Based Cystic Fibrosis Carrier Tests	. 19
PREFERRED STRATEGIES AND PROTOCOLS	
Who Should Provide Cystic Fibrosis Carrier Screening?	
Who Should Pay for Cystic Fibrosis Carrier Screening?	. 23
Strategies for Screening Various Populations	.23
PROFESSIONAL CAPACITY	
ISSUES TO BE ADDRESSED BEFORE IMPLEMENTATION	
SUMMARY	
CHAPTER 3 REFERENCES	. 28
Chapter 4. Summary	. 31
•	
Appendix A. Survey Method	
Appendix B. Survey Instrument**	36
Appendix C. Acronyms and Glossary	, 48
Figures	
<u> </u>	
1-1. Inheritance of Cystic Fibrosis	. l
1-2. Cystic Fibrosis Mutation Test Results at 85 Percent Sensitivity	
2-1. Geographic Distribution of Survey Respondents	
2-2. primary Service Areas of Respondents	8
2-3. Average Hours Spent Per Week on Public Education	
2-4. Racial/Ethnic Background of Clinical Genetics Clientele	. 9
2-5. Age Distribution of Genetics Clientele	9
2-6. Frequency of Patients Seen by Major Areas of Clinical Practice	
2-7. Number of Cystic Fibrosis Patients or Families Seen in Genetics Units in 1990	11

2-8. Health Care Coverage for Genetics Clientele
2-9. General Types of Health Care Coverage for Genetics Clientele
2-10. Third-Party Reimbursement for General Genetic Counseling and Counseling
Specifically for Cystic Fibrosis
3-1. Opinions on Optimal Rate of Detection
3-2. Frequency of Requests for Cystic Fibrosis Carrier Screening/Testing,
January-June1991
3-3. Comparison of Requests for Cystic Fibrosis Carrier Screening/TestingBetween
January-June 1991 and Past 2 Years
3-4. Opinions Regarding Genetic Counseling of Individuals with a Positive Family History
Family History
Family History
3-6. Opinions Regarding the Need for Informed Consent Prior to Cystic Fibrosis
Carrier Screening
3-7. Opinions Regarding the Use of Educational Materials as aSource of Information
About Cystic Fibrosis Carrier Screening
3-8. Extent to Which Various Groups Should Be Involved with Cystic Fibrosis
Pretest Education
3-9. Opinions Regarding the Need for More Genetic Counselors
Tables
1-1. A Priori Carrier Risks for Cystic Fibrosis
2-1. Geographic Concentration of Survey Respondents
2-2. Primary Work Setting
2-3. Average Weekly Schedule of Genetic Counselor or Nurse in Genetics
2-4. Formats for Genetic Counseling
2-5. Most Common Diseases for Which Carrier Screening/Testing Is Offered
2-6. Average Fees and Knowledge of Fees for Genetic Services
2-7. Fees for General Counseling
2-8. Difficulties in Obtaining or Retaining Health Insurance After Genetic Tests
2-9. Case Descriptions of Genetic Testing and Health Insurance Problems
3-1. A Priori Carrier Risks for Cystic Fibrosis
3-2. Sources of Information About New Advances in Human Genetics
3-3. Likelihood of Introducing the Topic of DNA Testing for Cystic Fibrosis
3-4. Specific Policies Regarding DNA Testing for Cystic Fibrosis
3-5. Minimal Criteria for Cystic Fibrosis Carrier Screening Protocol
3-6. Types of Genetic Analyses Provided for Cystic Fibrosis Screening Testing
3-7. Cystic Fibrosis Mutations Routinely Analyzed
3-8. Preferred Organizations for Implementation of Voluntary Cystic Fibrosis
Carrier Screening
3-10. Who Should Pay for Cystic Fibrosis Carrier Screening?
3-n Target Populations for Cystic Fibrosis Carrier Screening
3-n. Target Populations for Cystic Fibrosis Carrier Screening
3-12. Frequency of Patients Seen by Major Areas of Clinical Practice
3-12. Frequency of Patients Seen by Major Areas of Clinical Practice
3-12. Frequency of Patients Seen by Major Areas of Clinical Practice